 Vascular endothelial growth factor-D (VEGF-D) polypeptides |
| OF THE INVENTION The invention will now be described in detail by reference to the figures, and to ... |
|
| Methods for treating viral infection using IL-28 and IL-29 |
| We claim: 1. A method of treating a viral infection comprising administering to an ... |
|
| Method of manufacturing an electrohydraulic probe |
| OF THE INVENTION Referring to FIG. 1 there is shown a diagrammatical view of the bladder 2, ureter ... |
|
| Releasable linkage and compositions containing same |
| Accordingly, it is an object of the invention to provide a compound where a ligand is covalently ... |
|
| Solid phase dispersion of quinolone or naphthyridonecarboxylic acids |
| What is claimed is: 1. A solid phase dispersion comprising a micronized quinolinecarboxylic acid or ... |
|
| Peptide, process for its preparation and pharmaceutical composition containing same |
| We claim: 1. pGlu-Pro-Pro-Gly-Gly-Ser-Lys-Val-Ile-Leu-Phe. 2. A pharmaceutical composition for cell-... |
|
| Stable pharmaceutical composition and method for its production |
| It is an object of the present invention to provide a stable pharmaceutical composition wherein the ... |
|
| Peptide, a method for its preparation and a pharmaceutical composition containing the peptide |
| OF THE PREFERRED EMBODIMENT The following standard abbreviations for the amino acid residues are ... |
|
| Mimotopes and anti-mimotopes of human platelet glycoprotein Ib/IX |
| The invention provides an isolated peptide that functionally mimics a binding site for a ... |
|
|
Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
| Details |
Inventors: Kuberasampath, Thangavel; Cohen, Charles M.; Oppermann, Hermann; Ozkaynak, Engin; Rueger, David C.; Pang, Roy H. L.;
Assignee: Creative BioMolecules, Inc. (Hopkinton, MA)
Primary Examiner: Fleisher; Mindy
Assistant Examiner: Schwartzman; Robert
Attorney, Agent or Firm: Testa, Hurwitz & Thibeault, LLP
The invention is a treatment for increasing the bone mass or preventing bone loss in an individual afflicted with a bone disease which includes administering to the individual a morphogen in a therapeutically effective amount so as to maintain or stimulate bone formation. |
|
DETAILED DESCRIPTION The present invention provides methods and compositions for inhibiting loss of bone mass, and/or for stimulating bone formation in mammals, particularly humans.
In one aspect, the invention features a therapeutic treatment method and composition for preventing loss of bone mass and/or for increasing bone mass in a mammal which includes administering to the individual a therapeutically effective morphogen in an amount and for a time sufficient to inhibit the loss of bone mass, and/or to increase bone mass in the individual.
In another aspect, the invention features a therapeutic treatment method and composition for preventing loss of bone mass and/or for increasing bone mass in a mammal which includes administering to the mammal a compound that stimulates in vivo a therapeutically effective concentration of an endogenous morphogen in the body of the mammal sufficient to prevent loss of and/or to increase bone mass in the individual.
These compounds are referred to herein as morphogen-stimulating agents, and are understood to include substances which, when administered to a mammal, act on tissue(s) or organ(s) that normally are responsible for, or capable of, producing a morphogen and/or secreting a morphogen, and which cause the endogenous level of the morphogen to be altered.
The agent may act, for example, by stimulating expression and/or secretion of an endogenous morphogen.
The morphogens described herein are believed to play a significant role in maintaining appropriate bone mass in an individual.
Thus, a morphogen may be administered according to the invention to any individual who requires assistance in maintaining appropriate bone mass and/or who suffers from a bone remodeling imbalance.
For example, the morphogen or morphogen-stimulating agent may be administered according to the invention to an adult suffering from renal failure to prevent bone deterioration which is associated with that disease, e.
g.
, to correct bone loss due to late stage kidney failure.
Similarly, the administration of a morphogen to a child suffering from renal failure is expected not only to alleviate loss of bone mass in the child, but also to stimulate bone formation and thus growth
|
|
Gene Therapy 
